Table 2.
Cox proportional hazards model for time to death in recipients of diabetic vs. non-diabetic donor kidneys
Univariate Analysis | Multivariable Analysis* | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
HR | SE | z | p-value | 95% CI | HR | SE | z | p-value | 95% CI | |
Donor Characteristics | ||||||||||
Diabetes | 1.344 | 0.026 | 15.25 | < 0.001 | 1.294-1.396 | 1.186 | 0.027 | 7.48 | < 0.001 | 1.134-1.240 |
ECD | 1.702 | 0.019 | 48.33 | < 0.001 | 1.667-1.739 | |||||
Obese (BMI >=30) | 1.032 | 0.012 | 2.77 | 0.006 | 1.009-1.055 | |||||
Recipient Characteristics | ||||||||||
Age > 40 | 2.172 | 0.027 | 62.03 | < 0.001 | 2.120-2.226 | 1.995 | 0.031 | 44.44 | < 0.001 | 1.935-2.056 |
Male | 1.182 | 0.011 | 18.16 | < 0.001 | 1.160-1.203 | 1.087 | 0.012 | 7.40 | < 0.001 | 1.063-1.111 |
African American Race | 1.098 | 0.011 | 9.58 | < 0.001 | 1.077-1.119 | 1.069 | 0.013 | 5.47 | < 0.001 | 1.044-1.095 |
Pre-Transplant Dialysis** | 1.024 | 0.001 | 18.91 | < 0.001 | 1.022-1.027 | 1.025 | 0.002 | 15.75 | < 0.001 | 1.022-1.028 |
Time on Waitlist (days) | 1.000 | 0.000 | −4.59 | < 0.001 | 1.000-1.000 | |||||
Prior Renal Transplant | 0.910 | 0.013 | −6.49 | < 0.001 | 0.885-0.936 | 1.154 | 0.022 | 7.36 | < 0.001 | 1.111-1.198 |
HCV+ | 1.540 | 0.026 | 25.55 | < 0.001 | 1.489-1.591 | 1.426 | 0.028 | 18.01 | < 0.001 | 1.372-1.482 |
Max PRA ≥30 | 0.964 | 0.011 | −3.18 | 0.001 | 0.943-0.986 | 0.954 | 0.015 | −3.03 | 0.002 | 0.926-0.983 |
≥ 1 HLA Mismatch | 1.155 | 0.017 | 9.94 | < 0.001 | 1.123-1.189 | |||||
Pre-Transplant Diabetes** | 1.024 | 0.000 | 64.14 | < 0.001 | 1.024-1.025 | 1.020 | 0.000 | 49.16 | < 0.001 | 1.020-1.021 |
Obese (BMI >=30) | 1.116 | 0.011 | 10.83 | < 0.001 | 1.094-1.138 | |||||
Cold Ischemia Time | 1.008 | 0.001 | 16.41 | < 0.001 | 1.007-1.009 | |||||
Delayed Graft Function | 1.662 | 0.016 | 52.54 | < 0.001 | 1.631-1.694 | |||||
Acute Rejection at 1 Year | 1.416 | 0.017 | 28.98 | < 0.001 | 1.383-1.450 | |||||
No Induction Immunosuppression |
1.134 | 0.010 | 13.70 | < 0.001 | 1.114-1.155 |
Tacrolimus and the interaction term between tacrolimus and time were also included in the multivariable model
Included as an interaction term along with duration of dialysis or diabetes, as appropriate